ACOG · Alpha Cognition Inc.

Track ACOG — free

$8.90 +0.00 (+0.00%) At close · Sep 11

Rebalance outlook locked

Market Cap

$192.30M

21.78M

Up next

Latest filing: 10-Q

filed Aug 13, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$15.26M

Trailing 12 months

Net income (TTM)

−$21.01M

Trailing 12 months

Revenue growth YoY

+267.6%

Year over year

Operating margin

-174.7%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-16.2%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$41.38M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+35.9%

Year over year · more shares

Price change (1Y)

-7.8%

Trailing year

Short interest

1.0%

Latest settlement · 1.0 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Neutral Momentum Very Strong Sentiment Neutral Fundamentals Fair Quant / Vol Very High

Market backdrop VIX 15.8 · calm Equity put/call 0.60

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg +33%

above

Price vs 50-day avg +2%

above

RSI (14) 47

neutral

MACD trend Negative

52-week position 83%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Strong

1-month return +3%

trailing

6-month return +56%

trailing

YTD return +37%

this year

Relative strength +38%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $9 › 200d $7 — 50d above 200d

Institutional flow Flat

0% holders QoQ · +1 funds added

Insider flow Accumulating

Net +$3.1M over 90 days · 0% sells

Short interest Rising

0.97% of float · ▲ +3.6% MoM · 1.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

25 holders — mid 1-yr range

Squeeze score 38

low risk · 0–100

Fundamentals

Fair

EPS growth +42%

Y/Y

Free cash flow $-20.7M

Quant / Vol

risk profile

Very High

Volatility 66%

annualized · 1-yr

Max drawdown −54%

past year

ATR 6.9%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the Earnings Call filed Mar 31, 2026

Operating expense · full year 2026 Initiated $54M – $58M

Full year 2026 expense guidance · full year 2026 Initiated $54M – $58M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral

1 · 4 · 2

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+33% Bullish

Price vs 50-day avg

+2% Bullish

RSI (14)

47 Neutral

MACD trend

Negative Bearish

52-week position

83% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $9 › 200d $7 — 50d above 200d

Institutional flow Flat

0% holders QoQ · +1 funds added

Insider flow Accumulating

Net +$3.1M over 90 days · 0% sells

Short interest Rising

0.97% of float · ▲ +3.6% MoM · 1.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

25 holders — mid 1-yr range

Price context

position in its 52-week range

Range low $5 Now $9 · 83% Range high $10

vs 200-day avg +33% vs 50-day avg +2%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
ACOG Alpha Cognition Inc. this stock	$192.30M	+36.9%	—	—	1.0%
VRTX Vertex Pharmaceuticals Inc / Ma	$130.40B	+13.7%	+46.2%	30.0	1.8%
REGN Regeneron Pharmaceuticals, Inc.	$80.46B	+1.2%	+20.8%	19.4	2.5%
ARGX Argenx SE	$61.60B	+17.1%	—	—	2.0%
MRNA Moderna, Inc.	$57.48B	+388.2%	+4.3%	—	9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

% held: 48.1%
Net QoQ: -63.3K sh
Top holder: Opaleye Management Inc.

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Rising

Shares short

211.3K

Days to cover: 1.0d
Change: +7.3K sh

View

Short Volume

Short vol %

20%

As of: Sep 11, 2026

Short Total

View

Fails to Deliver

FTD shares

336

Value: $3.0K
As of: Aug 13, 2026

View

Off-Exchange

Off-exchange %

55.4%

Week of: Aug 3, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net buying

Net (90d)

+$3.1M

Buyers / Sellers: 2 / 0

Buyers Sellers

View

Financials

Revenue (FY)

$10.2M

Net income (FY): $-20.7M
EPS diluted: $-1.18

View

Filings

SEC Filings

Latest

10-Q

Filed: Aug 13, 2026
This year: 12

View

Exempt Offerings

Offering

$346.9K

Filed: Nov 18, 2024

View

Earnings & Events

Earnings Calls

Last call

Mar 31, 2026

View

Performance

	5D	20D	120D	MTD	YTD
ACOG	-3.4%	+3.1%	+55.9%	-4.0%	+36.9%
SPY	-1.2%	-1.8%	+17.8%	-0.4%	+12.1%
vs SPY	-2.2%	+4.9%	+38.0%	-3.6%	+24.8%

Key facts CIK 1655923 CUSIP 02074J501 13F (30d) 19 filings 19 filers Visit website Investor relations

ACOG · Alpha Cognition Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance